Icsori (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces the activation and migration of inflammatory cells, leading to decreased airway swelling, mucus production, and hyper‑responsiveness.

The specific dose of Icsori is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for fluticasone propionate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances with the patient before prescribing.

To request Icsori, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Icsori (fluticasone propionate) is a high‑potency inhaled corticosteroid with strong anti‑inflammatory activity, comparable to other agents such as budesonide or beclomethasone. Its once‑daily dosing and favorable lung deposition profile make it a common choice for maintenance therapy, though individual response and side‑effect profiles may differ.

Store Icsori at ambient temperature, preferably below 25 °C. Keep the inhaler in its original packaging, protect it from moisture and direct sunlight, and ensure the mouthpiece remains clean to maintain dose accuracy.

Icsori is delivered via inhalation using a metered‑dose inhaler or a dry‑powder device, depending on the formulation supplied. Patients should exhale fully, place the device in their mouth, inhale slowly and deeply while actuating the inhaler, then hold their breath for several seconds before exhaling.

Serious risks include adrenal suppression, increased susceptibility to pneumonia (especially in COPD patients), severe allergic reactions, and potential reductions in bone mineral density with long‑term use. Patients should be monitored regularly for signs of these complications.

Icsori is contraindicated in individuals with a known hypersensitivity to fluticasone propionate or any component of the inhaler. It should also be avoided in patients with active, untreated infections of the respiratory tract until the infection is resolved.